News related to Imitrex (Sumatriptan) and/or conditions it is approved for
APP Pharmaceuticals Receives Approval For Sumatriptan Succinate Injection, USP
Source: Headache / Migraine News From Medical News Today [2009.10.09]
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Sumatriptan Succinate Injection, USP, in two dosage strengths. Sumatriptan Succinate Injection is therapeutically equivalent to the reference-listed drug Imitrex®, which is marketed by the innovator GlaxoSmithKline.
Zogenix And Astellas Announce Data Published Showing The Benefits Of SUMAVEL(TM) DosePro(TM) Needle-Free Delivery System
Source: Headache / Migraine News From Medical News Today [2009.10.23]
Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, and Astellas Pharma US, Inc. ("Astellas") announced that positive results from two clinical studies of new SUMAVEL DosePro (sumatriptan injection) needle-free delivery system will be published in the November 2009 issue of Headache. SUMAVEL DosePro, was recently approved by the FDA to treat acute migraine, with or without aura, and cluster headache.
NovaDel Article Published In Headache: The Journal Of Head And Face Pain
Source: Headache / Migraine News From Medical News Today [2009.09.03]
NovaDel Pharma Inc. (NYSE AMEX: NVD) announced that an article titled "Rapid Oral Transmucosal Absorption of Sumatriptan, and Pharmacodynamics in Acute Migraine" was published online on June 22, 2009 in the peer-reviewed journal Headache: The Journal of Head and Face Pain. NovaDel conducted two clinical trials evaluating sumatriptan administered via its oral spray drug delivery technology.
|
